Sanofi has acquired two drug companies so far in 2018. Stephane de Sakutin / AFP via Getty Images

Pharmaceutical giants are once again acquiring smaller biotechnology companies after a lull in activity — deals that become a lot easier for drug companies to stomach after the Republican tax overhaul allowed them to repatriate overseas cash.

Here are some of the most recent pharma deals:

  • Today: French drug maker Sanofi agreed to buy Ablynx for $4.8 billion, just one week after it said it is buying Bioverativ for $11.6 billion.
  • Jan. 22: Celgene acquired Juno Therapeutics for $9 billion, cementing its spot in the CAR-T race for developing innovative, and expensive, cancer therapies. The Juno deal came just weeks after Celgene nabbed Impact Biosciences for up to $7 billion.
  • 2017: It was slow, but Gilead made noise with its $11.9 billion deal for Kite Pharma.

Go deeper

The Biden blowout scenario

Joe Biden speaks at an outdoor Black Economic Summit in Charlotte yesterday. Photo: Kevin Lamarque/Reuters

Joe Biden or President Trump could win the election narrowly — but only one in a popular and electoral vote blowout. 

Why it matters: A Biden blowout would mean a Democratic Senate, a bigger Democratic House and a huge political and policy shift nationwide.

2 hours ago - Technology

Justice's moves ring Big Tech with regulatory threats

Illustration: Annelise Capossela/Axios

The Department of Justice proposed legislation to curb liability protections for tech platforms and moved a step closer toward an antitrust lawsuit against Google Wednesday.

The big picture: As President Trump faces re-election, lawmakers and regulators are hurriedly wrapping up investigations and circling Big Tech with regulatory threats.

Democrats' mail voting pivot

Illustration: Sarah Grillo/Axios

Democrats spent the early months of the coronavirus pandemic urging their base to vote absentee. But as threats of U.S. Postal Service delays, Team Trump litigation and higher ballot rejection rates become clearer, many are pivoting to promote more in-person voting as well.

Why it matters: Democrats are exponentially more likely to vote by mail than Republicans this year — and if enough mail-in ballots are lost, rejected on a technicality or undercounted, it could change the outcome of the presidential election or other key races.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!